Please login to the form below

Not currently logged in

AstraZeneca and Ionis sign $3.6bn deal for eplontersen


The liver-targeted antisense therapy is in phase 3 trials for the treatment of transthyretin amyloidosis, a systemic, progressive and fatal condition

AstraZeneca signs for-profit agreements for its COVID-19 vaccine

AZ NEWThe for-profit deals are aimed to ‘progressively transition the vaccine to modest profitability’ as COVID-19 moves from a pandemic to an endemic disease

Pfizer's 2021 revenue predictions soar to $82bn

Pfizer NY headquartersStrong third-quarter revenues of $24.1bn lifted by sales of its BioNTech-partnered COVID-19 vaccine Comirnaty see Pfizer raise its 2021 revenue guidance to $82bn

Merck’s $11.5bn acquisition of Acceleron delayed

Merck & Co HQMerck’s acquisition of Acceleron will take longer than expected as it refiles its paperwork, giving the FTC more time for review and itself more time to sell the deal to

Gilead sales rise by 13%, buoyed by anti-COVID-19 drug Veklury

GileadThe company has had a ‘very strong’ third quarter in spite of a sharp decline in its HIV portfolio due to generic competition

Sanofi sees double-digit growth driven by ‘megabrand’ Dupixent

SanofiWith strong growth in specialty care, vaccines and consumer health seeing sales rise by 10% in the third quarter, Sanofi now expects earnings to grow by 14% in 2021

BMS reports strong growth as its Q3 results beat predictions

BMS buildingWith revenues for the third quarter up by 10%, BMS hopes growth for Opdivo, Eliquis and new launches will offset inevitable generic competition for Revlimid

Sandoz completes acquisition of GSK’s cephalosporin business

Sandoz NovartisThe acquisition confirms Sandoz’ commitment to antibiotics, following the announcement of further investment plans for European-based manufacturing network

AZ buys Caelum Biosciences for $500m

AZ NEWAfter AstraZeneca’s Alexion acquires all remaining equity in Caelum next week it will 'advance and accelerate' ongoing clinical development

Business in the USAHealth coverage across state lines

Despite a total lack of legislative wins, the new administration has made its presence felt at home and abroad

  • Ho_Ung_KimStanding out in a crowd

    Celltrion Healthcare’s Ho-Ung Kim on pricing, market access and regulatory challenges for successfully developing biosimilars

  • HeadsThe diseased organisation

    Like humans, organisations can be afflicted by genetic disorders that hinder performance and threaten survival but these can be understood and cured

COVID-19 Updates and Daily News

Featured jobs


Add my company

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....
Hybrid working: Insights and tips for success
Porterhouse Medical has thrived by embracing a hybrid approach to work. Our article looks at hybrid working and provides some tips for success...
The doctor will text you now: Why healthcare providers cannot underestimate the importance of communicating change
Healthcare communication needs to switch from ‘transmit’ to ‘receive’, listening to what patients need and embracing the plethora of communication tools wholeheartedly....